D Geho

 D Geho

D Geho

  • Courses1
  • Reviews1

Biography

George Mason University - Biology

Head of Imaging at Vertex Pharmaceuticals
Pharmaceuticals
David
Geho
Cambridge, Massachusetts
Board-certified physician-scientist and experienced leader in Translational R&D


Experience

  • Case Western Reserve University School of Medicine

    Adjunct Professor

    D worked at Case Western Reserve University School of Medicine as a Adjunct Professor

  • Vertex Pharmaceuticals

    Head of Translational Biology

    D worked at Vertex Pharmaceuticals as a Head of Translational Biology

  • Vertex Pharmaceuticals

    Head of Imaging

    D worked at Vertex Pharmaceuticals as a Head of Imaging

  • Vertex Pharmaceuticals

    Global Head of Clinical Biomarkers

    D worked at Vertex Pharmaceuticals as a Global Head of Clinical Biomarkers

  • Merck

    Director, Imaging

    D worked at Merck as a Director, Imaging

  • Roche

    Senior Leader, Translational Medicine-Oncology

    D worked at Roche as a Senior Leader, Translational Medicine-Oncology

  • GE Healthcare

    Clinical Project Leader

    Clinical Development of Molecular Imaging Radiotracers

Education

  • Eastman School of Music

    Bachelor of Music

    French Horn Performance

  • Case Western Reserve University School of Medicine

    MD and PH.D.



  • Case Western Reserve University School of Medicine

    Adjunct Professor



  • National Cancer Institute

    Medical Staff Fellow

    Anatomic Pathology Residency

  • Smart hydrogel particles for biomarker harvesting


    See application of this nanotechnology at Ceres Nanosciences (http://www.ceresnano.com)

  • Method of isolating analytes from a sample


    See application of this nanotechnology at Ceres Nanosciences (http://www.ceresnano.com)

  • MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST


    This biomarker invented to select patients for MDM2 inhibitor therapy is further described the the British Journal of Haematology (http://onlinelibrary.wiley.com/doi/10.1111/bjh.13411/abstract)

  • Tissue preservation and fixation method


    Novel fixative that enables molecular analyses of proteins while preserving morphological detail. Currently sold by Grace BioLabs as TheraLin Universal Tissue Fixative (http://www.gracebio.com/group/theralin/theralinr-universal-tissue-fixative.html)

Publications

  • Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

    The Lancet Oncology

  • Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

    The Lancet Oncology

  • Nanoparticles: potential biomarker harvesters

    Current Opinion in Chemical Biology

  • Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

    The Lancet Oncology

  • Nanoparticles: potential biomarker harvesters

    Current Opinion in Chemical Biology

  • RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response.

    Clinical Cancer Rearch

  • Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

    The Lancet Oncology

  • Nanoparticles: potential biomarker harvesters

    Current Opinion in Chemical Biology

  • RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response.

    Clinical Cancer Rearch

  • Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation.

    Nano Letters

    See application of this technology at Ceres Nanosciences (www.ceresnano.com)

  • Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

    The Lancet Oncology

  • Nanoparticles: potential biomarker harvesters

    Current Opinion in Chemical Biology

  • RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response.

    Clinical Cancer Rearch

  • Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation.

    Nano Letters

    See application of this technology at Ceres Nanosciences (www.ceresnano.com)

  • Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.

    Clinical Cancer Research

  • Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

    The Lancet Oncology

  • Nanoparticles: potential biomarker harvesters

    Current Opinion in Chemical Biology

  • RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response.

    Clinical Cancer Rearch

  • Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation.

    Nano Letters

    See application of this technology at Ceres Nanosciences (www.ceresnano.com)

  • Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.

    Clinical Cancer Research

  • MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.

    British Journal of Haematology